Labeled for this condition
Medicines for breast cancer
44 medicines have an FDA label indicated for breast cancer; 20 are listed from generic labelers and 1 has a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for breast cancer?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Estradiol | Climara, Divigel, Minivelle | 40 labelers | $0.0635 per tablet 1 mg tablet | Yes | No current entry | 60 |
| Testosterone | Jatenzo, Xyosted, Kyzatrex | 33 labelers | $11.39 per mL 200 mg/mL | No | No current entry | 70 |
| Everolimus | Afinitor, Zortress, Torpenz | 14 labelers | $26.32 per tablet 10 mg tablet | No | A presentation being discontinued | 5 |
| Methotrexate | Rasuvo, Otrexup, Jylamvo | 29 labelers | $0.158 per tablet 2.5 mg tablet | Yes | In shortage | 8 |
| Docetaxel | Beizray, Docivyx | 14 labelers | n/a | Yes | A presentation being discontinued | 7 |
| Doxorubicin | Doxil | 16 labelers | n/a | Yes | No current entry | 5 |
| Paclitaxel | Abraxane | 19 labelers | n/a | Yes | No current entry | 2 |
| Gemcitabine | Avgemsi, Inlexzo | 10 labelers | n/a | No | No current entry | 5 |
| Anastrozole | Arimidex | 24 labelers | $0.142 per tablet 1 mg tablet | No | No current entry | 4 |
| Capecitabine | Xeloda | 18 labelers | $0.456 per tablet 500 mg tablet | Yes | No current entry | 4 |
| Fulvestrant | Faslodex, Cligavyx | 19 labelers | n/a | No | A presentation being discontinued | 2 |
| Letrozole | Femara | 19 labelers | $0.145 per tablet 2.5 mg tablet | No | No current entry | 1 |
| Raloxifene | Evista | 17 labelers | $0.223 per tablet 60 mg tablet | Yes | No current entry | 1 |
| Estrogens conjugated | Premarin | 1 labeler | $5.47 per tablet 0.625 mg tablet | Yes | No current entry | 0 |
| Tamoxifen | Soltamox | 10 labelers | $0.277 per tablet 20 mg tablet | Yes | No current entry | 0 |
| Eribulin | Halaven | 14 labelers | n/a | No | No current entry | 0 |
| Exemestane | Aromasin | 10 labelers | $0.748 per tablet 25 mg tablet | No | No current entry | 0 |
| Talazoparib | Talzenna | none listed | n/a | No | No current entry | 0 |
| Trastuzumab | Ogivri, Kanjinti, Herzuma | none listed | n/a | Yes | No current entry | 0 |
| Palbociclib | Ibrance | none listed | n/a | No | A presentation being discontinued | 0 |
| Abemaciclib | Verzenio | none listed | n/a | No | No current entry | 0 |
| Lapatinib ditosylate | Tykerb | 3 labelers | n/a | Yes | No current entry | 0 |
| Olaparib | Lynparza | none listed | n/a | No | No current entry | 0 |
| Methyltestosterone | Methitest | 2 labelers | n/a | No | No current entry | 0 |
| Ribociclib | Kisqali | none listed | $289.72 per unit 600 mg daily dose | No | No current entry | 0 |
| Toremifene | Fareston | 2 labelers | $19.60 per tablet 60 mg tablet | Yes | No current entry | 0 |
| Trastuzumab-strf | Hercessi | none listed | n/a | Yes | No current entry | 0 |
| Berahyaluronidase alfa and pembrolizumab | Keytruda | none listed | n/a | No | No current entry | 0 |
| Capivasertib | Truqap | none listed | n/a | No | No current entry | 0 |
| Elacestrant | Orserdu | none listed | n/a | No | No current entry | 0 |
| Goserelin | Zoladex | none listed | n/a | No | No current entry | 0 |
| Hyaluronidase and pertuzumab and trastuzumab | Phesgo | none listed | n/a | Yes | No current entry | 0 |
| Ixabepilone | Ixempra | none listed | n/a | Yes | No current entry | 0 |
| Margetuximab | Margenza | none listed | n/a | Yes | No current entry | 0 |
| Neratinib | Nerlynx | none listed | n/a | No | No current entry | 0 |
| Trastuzumab emtansine | Kadcyla | none listed | n/a | Yes | No current entry | 0 |
| Tucatinib | Tukysa | none listed | n/a | No | No current entry | 0 |
| Datopotamab deruxtecan | Datroway | none listed | n/a | No | No current entry | 0 |
| Hyaluronidase and trastuzumab | Herceptin | none listed | n/a | Yes | No current entry | 0 |
| Imlunestrant | Inluriyo | none listed | n/a | No | No current entry | 0 |
| Pembrolizumab | Keytruda | none listed | n/a | No | No current entry | 1 |
| Pertuzumab | Perjeta | none listed | n/a | Yes | No current entry | 1 |
| Sacituzumab govitecan | Trodelvy | none listed | n/a | Yes | No current entry | 0 |
| Trastuzumab deruxtecan | Enhertu | none listed | n/a | Yes | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price